PT  - JOURNAL ARTICLE
AU  - Dancik, Garrett M.
AU  - Voutsas, Ioannis F.
AU  - Vlahopoulos, Spiros
TI  - Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia
AID  - 10.1101/2021.10.20.21265241
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.20.21265241
4099  - http://medrxiv.org/content/early/2021/10/26/2021.10.20.21265241.short
4100  - http://medrxiv.org/content/early/2021/10/26/2021.10.20.21265241.full
AB  - The expression and activity of enzymes that belong to the aldehyde dehydrogenases is a characteristic of both normal and malignant stem cells. ALDH1A1 is an enzyme critical in cancer stem cells. In acute myeloid leukemia (AML), ALDH1A1 protects leukemia-initiating cells from a number of antineoplastic agents, which include inhibitors of protein tyrosine kinases. Furthermore, ALDH1A1 proves vital for the establishment of human AML xenografts in mice. We review here important studies characterizing the role of ALDH1A1 in AML and its potential as a therapeutic target. We also analyze datasets from leading studies, and show that decreased ALDH1A1 RNA expression consistently characterizes the AML patient risk group with a favorable prognosis, while there is a consistent association of high ALDH1A1 RNA expression with high risk and poor overall survival. Our review and analysis reinforces the notion to employ both novel as well as existing inhibitors of the ALDH1A1 protein against AML.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported, in part, by a grant from the American Association of University Professors and Connecticut State University Board of Regents (YRDA01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.AKT/PKBRAC-alpha serine/threonine-protein kinaseALDHAldehyde dehydrogenaseAMLAcute myeloid leukemiaara-ccytosine arabinosideCEBPACCAAT enhancer binding protein alphadeldeletionELNEuropean LeukemiaNetEVI1ecotropic viral integration site 1FLT3Fms-like tyrosine kinase-3FLT3 ITDinternal tandem duplication of FLT3invinversionMTOR, kinasemechanistic/mammalian target of rapamycinNFκBnuclear factor kappa BNOD/SCIDnonobese diabetic/severe combined immunodeficiency miceNPM1nucleophosmin 1OGG18-oxoguanine glycosylasePD-L1Programmed death-ligand 1PI3Kphosphatidylinositol 3-kinasettranslocationTLX1/HOX11T cell leukemia/homeobox 1